“We were probably one of the lucky few that was able to go out last fall and have such a strong and successful IPO,” Bicara ...

Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.

Merck is holding strong among billionaire favorites, despite the broader healthcare sector dodging investor affection like a ...

The global surgical sutures market size has witnessed significant advancements in recent years, driven by an increasing number of surgical procedures and improvements in medical technologies. Surgical ...

Shares of Summit Therapeutics SMMT rose more than 15% on Friday after the analysts at Cantor Fitzgerald and Truist Securities ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Summit Therapeutics (NASDAQ: SMMT), and Viking Therapeutics (NASDAQ: VKTX) as stocks worth buying now. (CRISPR Therapeutics): Despite creating Casgevy, the first CRISPR-based gene-editing medicine to ...

A potential U.S. launch of this Chinese biotech's new lung cancer drug - which bested Merck's blockbuster Keytruda - is a key ...

Merck is juggling shareholder rebellion and market turbulence ahead of its annual meeting, with the company giving a firm thumbs-down to several investor proposals. This shareholder pushback adds a ...

While these stocks led growth in early 2020, their momentum eventually faded. This led to corrections instead of broadening. Investors began exploring second and third derivative trades stemming from ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

A consumer-driven weight loss market could put pharma at greater risk if a recession hits; the continued turmoil at FDA and other HHS agencies magnifies the uncertainty facing the industry; Lilly ...